Stem Cell Therapy for Osteogenesis Imperfecta

What This Article Covers

Osteogenesis imperfecta (OI), or “brittle bone disease,” is a rare genetic disorder causing fragile bones and frequent fractures, usually due to defective collagen. There is no cure; current care (bisphosphonates, bracing, surgery) manages symptoms rather than the underlying defect. A small number of academic trials, most notably the Karolinska Institute/University of Gothenburg-led BOOSTB4 study, are testing whether transplanted donor mesenchymal stem cells (MSCs) can reduce fractures and improve bone quality in severe OI. This article summarizes what has actually been shown and why this remains investigational, not an approved treatment.

Overview

OI is caused in most cases by mutations affecting type I collagen, the protein scaffold that gives bone its flexibility and strength. Severe forms (OI type III and severe type IV) can cause dozens of fractures before birth and through childhood, along with impaired growth and, in the most severe cases, early death. Because the defect is genetic and present in essentially every bone-forming cell, researchers have asked whether introducing healthy donor cells could supplement the patient's own defective bone-forming cells. Mesenchymal stem cells (MSCs), which can develop into bone-forming osteoblasts, are the primary cell type under investigation.

How It's Thought to Work

The rationale is cellular reinforcement, not gene correction. Donor MSCs — sourced in these trials from fetal liver tissue — are infused into the patient, either before birth (in utero, into the fetal circulation) or after birth (intravenously or into the bone marrow). The hypothesis is that some donor cells engraft in the recipient's bone and produce normal type I collagen, diluting the effect of the patient's own mutated collagen and improving bone strength. MSCs are also thought to have supportive “trophic” effects on the surrounding bone-forming environment, which may contribute to benefit independent of long-term engraftment.

What the Evidence Shows

The clearest human data come from Sweden. An early two-patient case series in Stem Cells Translational Medicine (Götherström et al., 2014) reported that children given prenatal and postnatal fetal MSC transplantation had no new fractures for extended periods and showed resumed or improved growth, with no acute toxicity or immune rejection — encouraging, but a very small first look.

That work led to BOOSTB4, an EU-funded, Karolinska Institute/University of Gothenburg-led phase I/II trial (coordinated by Cecilia Götherström) testing repeated fetal MSC doses, prenatally and postnatally, in children with severe OI. Its protocol was peer-reviewed, and a follow-on study, BOOST2B, testing additional dosing in a larger cohort, appeared as a protocol in Bone & Joint Open (2025).

In October 2025, researchers presented two-year BOOSTB4 follow-up data at the International Conference on Osteogenesis Imperfecta in Hong Kong, reported by Karolinska Institutet's news office and by the trial's commercial sponsor, BOOST Pharma. Findings included a roughly 70% fracture reduction in year one, rising to nearly 78% by year two versus each child's pre-treatment history, with more than half of treated children fracture-free in year two. Coordinator Cecilia Götherström called the fracture-free result “tremendously encouraging.” These figures come from a real, named academic trial with long-term follow-up — but so far they've been shared at a scientific conference and in institutional statements, not yet in a completed peer-reviewed results paper, and the enrolled population remains small, as is unavoidable for a rare disease.

Who Might Be a Candidate

Stem cell therapy for OI is not an available clinical treatment — it exists only inside formal research trials. In principle, the populations these trials have targeted are:

• Children and fetuses diagnosed with severe OI (type III or severe type IV), confirmed by collagen gene testing
• Families enrolled through academic centers running trials such as BOOSTB4 or BOOST2B, under formal research protocols and ethics oversight
• Cases where prenatal diagnosis allows consideration of in-utero treatment, alongside postnatal dosing
• Patients willing to accept an experimental, unapproved intervention with a still-limited track record

People with mild OI, or anyone seeking this outside a registered clinical trial, are not appropriate candidates — no regulated, direct-to-consumer version of this therapy exists.

Bottom Line

Donor mesenchymal stem cell transplantation for severe osteogenesis imperfecta is a genuinely promising research direction, not an approved therapy. Early case reports and the ongoing BOOSTB4/BOOST2B trials out of Sweden have produced real, encouraging signals — meaningfully reduced fracture rates and improved growth in some children — but the evidence still rests on small patient numbers, as is unavoidable in a rare disease, and the strongest recent results have so far appeared in conference presentations and institutional statements rather than a completed peer-reviewed efficacy paper. No stem cell therapy for OI is approved by the FDA or EMA; standard care remains bisphosphonates, physical therapy, bracing, and orthopedic surgery. Anyone interested should pursue this only through registered academic trials, not clinics marketing unproven “stem cell treatments” for OI.